Liquid Biopsy 🩸🧬
Liquid biopsy represents a paradigm shift in oncology, offering a non-invasive method for disease analysis by sampling biological material from bodily fluids, primarily blood. Instead of relying on tissue samples, this technology analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes released by tumors. The primary utility lies in early cancer detection in high-risk populations, monitoring treatment response in real-time, and detecting minimal residual disease (MRD) after surgery or chemotherapy.
The ability to serially monitor ctDNA allows clinicians to identify resistance mutations months before they appear on radiographic scans, enabling proactive changes to therapy. This technology is particularly valuable in cases where obtaining a tissue biopsy is technically difficult or too risky for the patient. Despite rapid advancements in sensitivity, technical challenges remain, including the low concentration of ctDNA in early-stage disease and the need for standardized, highly sensitive analytical platforms. The discussion should center on how liquid biopsy complements rather than replaces traditional imaging and tissue pathology, and its potential to facilitate personalized medicine by guiding therapeutic selection based on genetic profiling.